Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis

被引：2
作者：
Uprety, Dipesh [1 ]
Arjyal, Lubina [1 ]
Vallatharasu, Yazhini [1 ]
Bista, Amir [1 ]
Wittchow, Richard J. [1 ]
Marinier, David E. [1 ]
机构：
[1] Gundersen Hlth Syst, La Crosse, WI 54601 USA
来源：
CLINICAL LUNG CANCER | 2019年 / 20卷 / 05期
关键词：
Durable response; Immunotherapy; NSCLC; Pembrolizumab; Stage IV; PHASE-III; CHEMOTHERAPY;
D O I：
10.1016/j.cllc.2019.06.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E552 / E554
页数：3
相关论文
共 14 条
  • [1] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
    Forde, P. M.
    Chaft, J. E.
    Smith, K. N.
    Anagnostou, V.
    Cottrell, T. R.
    Hellmann, M. D.
    Zahurak, M.
    Yang, S. C.
    Jones, D. R.
    Broderick, S.
    Battafarano, R. J.
    Velez, M. J.
    Rekhtman, N.
    Olah, Z.
    Naidoo, J.
    Marrone, K. A.
    Verde, F.
    Guo, H.
    Zhang, J.
    Caushi, J. X.
    Chan, H. Y.
    Sidhom, J. -W.
    Scharpf, R. B.
    White, J.
    Gabrielson, E.
    Wang, H.
    Rosner, G. L.
    Rusch, V.
    Wolchok, J. D.
    Merghoub, T.
    Taube, J. M.
    Velculescu, V. E.
    Topalian, S. L.
    Brahmer, J. R.
    Pardoll, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) : 1976 - 1986
  • [2] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
  • [3] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
    Hellmann, M. D.
    Ciuleanu, T. -E.
    Pluzanski, A.
    Lee, J. S.
    Otterson, G. A.
    Audigier-Valette, C.
    Minenza, E.
    Linardou, H.
    Burgers, S.
    Salman, P.
    Borghaei, H.
    Ramalingam, S. S.
    Brahmer, J.
    Reck, M.
    O'Byrne, K. J.
    Geese, W. J.
    Green, G.
    Chang, H.
    Szustakowski, J.
    Bhagavatheeswaran, P.
    Healey, D.
    Fu, Y.
    Nathan, F.
    Paz-Ares, L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2093 - 2104
  • [4] Jimenez Aguilar E, 2018, 19 WORLD C LUNG CANC
  • [5] Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
    Molina, Julian R.
    Yang, Piii G.
    Cassivi, Stephen D.
    Schild, Steven E.
    Adjei, Alex A.
    [J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (05) : 584 - 594
  • [6] BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
    Norum, Jan
    Grindedal, Eli Marie
    Heramb, Cecilie
    Karsrud, Inga
    Ariansen, Sarah Louise
    Undlien, Dag Erik
    Schlichting, Ellen
    Maehle, Lovise
    [J]. ESMO OPEN, 2018, 3 (03)
  • [7] PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Socinski, Mark A.
    Garon, Edward B.
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Hermann, Robert C.
    Jotte, Robert M.
    Beck, Thaddeus
    Richards, Donald A.
    Guba, Susan C.
    Liu, Jingyi
    Frimodt-Moller, Bente
    John, William J.
    Obasaju, Coleman K.
    Pennella, Eduardo J.
    Bonomi, Philip
    Govindan, Ramaswamy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4349 - U77
  • [8] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
    Paz-Ares, L.
    Luft, A.
    Vicente, D.
    Tafreshi, A.
    Gumus, M.
    Mazieres, J.
    Hermes, B.
    Senler, F. Cay
    Csoszi, T.
    Fulop, A.
    Rodriguez-Cid, J.
    Wilson, J.
    Sugawara, S.
    Kato, T.
    Lee, K. H.
    Cheng, Y.
    Novello, S.
    Halmos, B.
    Li, X.
    Lubiniecki, G. M.
    Piperdi, B.
    Kowalski, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) : 2040 - 2051
  • [9] PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Louis
    Bidoli, Paolo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    Reck, Martin
    Corral, Jesus
    Melemed, Symantha
    John, William
    Chouaki, Nadia
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2895 - +
  • [10] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    Lubiniecki, Gregory M.
    Shentu, Yue
    Rangwala, Reshma
    Brahmer, Julie R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1823 - 1833
12